[eng] Utility Theory and Health Status measurement: the Debate QALYs vs HYEs . by Claude Le Pen . A vigorous debate has recently opposed int the field on the economic assessment of medical technologies two methods to value health states : the "Quality Adjusted Life Years" (QALYs) and the...

EPO markets have proven to be highly country-specific. EPO market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO/REF price differences may not be determining factors of BIOSIM-EPO uptakes. Prescription and substitution incentives to use BIOSIM-EPO appear to be determining factors...

[eng] Price regulation and competition patterns in the ethical drug industry in france. . This article gives the results of an econometric modelization of the ethical drugs price and quantity determination institutionnal process for France. From price and promotion elasticities, it is shown that...

[fre] Le papier présente un modèle d'analyse microéconomique d'une institution de production dramatique en envisageant différentes hypothèses de comportement : la politique de prix moyen et de qualité d'une organisation de type marchand est comparée aux politiques obtenues dans le cadre...

[eng] Public employment and distribution of income. Claude Le Pen. This paper investigates the influence of jniblic expenditure on distribution of income through the labour market.. The demand of labour from public administrations exercices a differentiel effect on each workers group on a labour...

An overview of the present state of development of pharmacoeconomics in France is given, and more specifically how it works, in what context it operates, what kind of studies it produces, what kind of results it reaches, and what kind of future it may expect. The main features of the French...

Contrary to the traditional view of the health care consumer as an economic agent whose sove-reignty is attenuated, we argue that he is far less ignorant and far less deprived of reason than it is supposed by the tutelary model of health economics. The reason lies in his enhanced level of...

The availability of the Diagnosis Related Group (DRG) system for determining hospital costs in some European countries has encouraged its use in pharmacoeconomic evaluations. The DRG system was developed in the US to provide data for prospective payments for hospitals. However, the financing of...

Price regulation and competition patterns in the ethical drug industry in france This article gives the results of an econometric modelization of the ethical drugs price and quantity determination institutionnal process for France. From price and promotion elasticities, it is shown that...